Literature DB >> 33258699

Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma.

Anna L Parks1, Swetha Kambhampati1, Bita Fakhri1, Charalambos Andreadis1, Lissa Gray1, Sandy W Wong1, Nina Shah1, Margaret C Fang2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33258699      PMCID： PMC8012226          DOI： 10.1080/10428194.2020.1852474

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  10 in total

Review 1.  Inflammation and thrombosis.

Authors:  C T Esmon
Journal:  J Thromb Haemost       Date:  2003-07       Impact factor: 5.824

2.  Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH.

Authors:  S Kaatz; D Ahmad; A C Spyropoulos; S Schulman
Journal:  J Thromb Haemost       Date:  2015-11       Impact factor: 5.824

Review 3.  Venous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis.

Authors:  Mohammad Faizan Zahid; M Hassan Murad; Mark R Litzow; William J Hogan; Mrinal S Patnaik; Alok Khorana; Alex C Spyropoulos; Shahrukh K Hashmi
Journal:  Ann Hematol       Date:  2016-04-22       Impact factor: 3.673

4.  Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study.

Authors:  Margaret C Fang; Dongjie Fan; Sue Hee Sung; Daniel M Witt; John R Schmelzer; Steven R Steinhubl; Steven H Yale; Alan S Go
Journal:  Med Care       Date:  2017-12       Impact factor: 2.983

5.  Lymphoma and venous thromboembolism: influence on mortality.

Authors:  Anjlee Mahajan; Ted Wun; Helen Chew; Richard H White
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

Review 6.  Thrombosis in multiple myeloma.

Authors:  Sigurdur Yngvi Kristinsson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

7.  Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events.

Authors:  Vanesa Caruso; Augusto Di Castelnuovo; Susana Meschengieser; Maria A Lazzari; Giovanni de Gaetano; Sergio Storti; Licia Iacoviello; Maria Benedetta Donati
Journal:  Blood       Date:  2010-04-08       Impact factor: 22.113

8.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.

Authors:  S Schulman; C Kearon
Journal:  J Thromb Haemost       Date:  2005-04       Impact factor: 5.824

9.  Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.

Authors:  Ana Cordeiro; Evandro D Bezerra; Alexandre V Hirayama; Joshua A Hill; Qian V Wu; Jenna Voutsinas; Mohamed L Sorror; Cameron J Turtle; David G Maloney; Merav Bar
Journal:  Biol Blood Marrow Transplant       Date:  2019-08-13       Impact factor: 5.742

Review 10.  Risk factors for venous thromboembolism.

Authors:  Frederick A Anderson; Frederick A Spencer
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690
  10 in total
  3 in total

1.  The correlation factors and prognostic significance of coagulation disorders after chimeric antigen receptor T cell therapy in hematological malignancies: a cohort study.

Authors:  Rujiao Dong; Yudi Wang; Yuanyuan Lin; Xiaohong Sun; Chongyun Xing; Yu Zhang; Haizhi Wang; Lihui Dai; Kang Yu; Songfu Jiang
Journal:  Ann Transl Med       Date:  2022-09

2.  Hemostasis and tumor immunity.

Authors:  Rachel Cantrell; Joseph S Palumbo
Journal:  Res Pract Thromb Haemost       Date:  2022-05-25

Review 3.  Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma.

Authors:  Claire Comerford; Siobhan Glavey; Jamie M O'Sullivan; John Quinn
Journal:  Cancer Drug Resist       Date:  2022-03-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.